Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2023 15:45 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; February 22, 2023 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
February 22, 2023 13:12 ET | Source: Genmab A/S

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Media ReleaseCopenhagen, Denmark, February 22, 2023 Genmab filed Form 20-F for the financial year 2022 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report...
February 22, 2023 11:12 ET | Source: Genmab A/S

Genmab Announces Initiation of Share Buy-Back Program

Company Announcement Repurchase of up to 220,000 sharesHonoring commitments under our Restricted Stock Unit programCompletion expected on March 31, 2023 COPENHAGEN, Denmark; February 22, 2023 –...
February 22, 2023 11:01 ET | Source: Genmab A/S

Genmab Publishes 2022 Annual Report

Company Announcement COPENHAGEN, Denmark; February 22, 2023 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2022. Below is a summary of business progress in...
January 24, 2023 14:00 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,408 restricted stock units to employees of the Company as well...
January 24, 2023 06:27 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022

Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 24,...
January 19, 2023 11:00 ET | Source: Genmab A/S

Correction to Company Announcement No. 1 of January 3, 2023

Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with shares and linked securities in...
January 03, 2023 12:31 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; January 3, 2023 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
January 02, 2023 07:56 ET | Source: Genmab A/S

Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; January 2, 2023Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 41st Annual J.P. Morgan...
December 21, 2022 07:00 ET | Source: Genmab A/S

Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Media Release COPENHAGEN, Denmark; December 21, 2022 JNDA submission supported by results of Japanese and global phase 2 clinical trials evaluating epcoritamab in patients with mature B-cell...